ARS Pharmaceuticals, Inc. SPRY 深 滬
已收盤 02-06 16:00:00 美东时间
10.03
+0.360
+3.72%
華盛通- 最 高10.05
- 今 開9.87
- 成交量 115.14万股
- 最 低 9.70
- 昨 收 9.67
- 總市值 9.91亿
- 52周最高 18.90
- 市盈率 靜 128.43
- 換手率 1.16%
- 52周最低 6.66
- 委 比 25.93%
- 總股本 9884.86万
- 歷史最高 63.41
- 量 比 0.87
- 振 幅 3.62%
- 歷史最低 2.55
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ARS Pharmaceuticals Gets Positive Opinion For Expanded Marketing Authorization For EURneffy By EMA's Committee For Medicinal Products For Human Use
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis,
02-02 21:18
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Vyome Holdings (NASDAQ:HIND) stock increased by 16.1% to $2.23 during ...
02-02 20:05
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the marketing authorization for EURneffy® to include a 1 mg nasal adrenaline spray for the emergency treatment of anaphylaxis in children weighing between 15 kg and 30 kg. This marks the first and only needle-free adrenaline option available for younger children in the European Union. The 1 mg dose will complement the previou...
02-02 13:00
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
California has joined 23 other states in the "neffy" inSchools program, enabling schools to receive free epinephrine nasal spray to address severe allergic reactions like anaphylaxis. ARS Pharmaceuticals' initiative aims to empower schools to respond quickly to emergencies, with over 8,000 schools already participating nationwide. The program provides two cartons of 1 mg and 2 mg doses of "neffy," a needle-free, portable solution designed for eas...
01-21 13:00
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying potential competition.
01-10 01:32
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
Aquestive Therapeutics shares fall after the FDA flags deficiencies in its Anaphylm allergy drug application, raising approval delay concerns despite the review remaining active.
01-10 00:28
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
ARS Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference in New York from Dec 2-4, 2025. Co-Founder Richard Lowenthal and Chief Commercial Officer Eric Karas will engage in a fireside chat with analyst David Amsellem on Dec 3 at 2:30 pm ET. The event will be webcast live and available for 90 days on the Company’s website. The biopharmaceutical company specializes in producing neffy®, an epinephrine nasal spray f...
2025-11-26 13:00
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
2025-11-10 19:12
ARS Pharmaceuticals Q3 EPS $(0.52) Misses $(0.47) Estimate, Sales $32.501M Beat $28.743M Estimate
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.47) by 10.17 percent. This is a 160 percent decrease over losses of $(0.20) per share
2025-11-10 19:00
Earnings Outlook For ARS Pharmaceuticals
ARS Pharmaceuticals (NASDAQ:SPRY) is set to give its latest quarterly earnings ...
2025-11-08 02:04
